SMARCA5

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 · O60264 · SMARCA5 on Sugi Atlas →

0 patent compounds predicted against SMARCA5, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SMARCA5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE2RECRUITING
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Adult Spinal Muscular Atrophy (SMA) China Registry nanACTIVE_NOT_RECRUITING
French Register of Patients With Spinal Muscular Atrophy nanRECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
An Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA) nanAPPROVED_FOR_MARKETING
Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America nanUNKNOWN
Natural History Study of Smith-Magenis Syndrome nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SMARCA5 binder may also engage these)

ProteinNameSimilarity
Q91ZW3 1.000 Q91ZW3 →
Q6PGB8 1.000 Q6PGB8 →
Q8RWY3 1.000 Q8RWY3 →
SMARCA1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1 1.000 landscape →
F4JY24 1.000 F4JY24 →
Q7G8Y3 1.000 Q7G8Y3 →
Q24368 1.000 Q24368 →
P41877 1.000 P41877 →
D3ZA12 0.997 D3ZA12 →
A3KFM7 0.997 A3KFM7 →
B6ZLK2 0.996 B6ZLK2 →
Q8TD26 0.995 Q8TD26 →
Q5A310 0.995 Q5A310 →
A9X4T1 0.994 A9X4T1 →
A5E3K3 0.994 A5E3K3 →
P38144 0.994 P38144 →
B5VE38 0.993 B5VE38 →
CHD1 Chromodomain-helicase-DNA-binding protein 1 0.993 landscape →
Q6FPT7 0.993 Q6FPT7 →
Q6CGD1 0.993 Q6CGD1 →
Q08773 0.993 Q08773 →
Q4TVV3 0.993 Q4TVV3 →
Q14562 0.993 Q14562 →
Q9Y4B4 0.993 Q9Y4B4 →
P32863 0.992 P32863 →
P40562 0.992 P40562 →
P40201 0.992 P40201 →
Q9S775 0.992 Q9S775 →
Q7ZU90 0.992 Q7ZU90 →
Q9UTP9 0.992 Q9UTP9 →